Richard Gregory Farrell

MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation.

DemeRx, Inc. provides biotechnology services. It focuses on drug addiction among patients coping with chronic pain. The company was founded by Deborah C. Mash on March 1, 2010 and is headquartered in Miami, FL.

Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA.

Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Mallinckrodt Brand Pharmaceuticals, Inc. engages in the manufacture of pharmaceutical and health products. The company was founded on September 23, 2015 and is headquartered in Hazelwood, MO.

Part of Bausch Health Cos., Inc., Biovail Laboratories International SRL develops, manufactures, and sells pharmaceutical products. The company is based in Saint Michael, Barbados.

Springlane GmbH develops and operates an online food and kitchenware shopping portal. It provides users with a web-based platform for searching and buying cooking equipment and kitchen accessories, such as cooking pots and pans, electronic grills, rice cookers, glassware, plates and cups, utensils, and table decoration. It also offers a selection of wine and gourmet food products. The company was founded by Lars Christian Wilde, Marius Till Fritzsche, Alexander Luik, Nils Wilde, and Björn Rust in 2012 and is headquartered in Dusseldorf, Germany.

AiVita Biomedical, Inc. operates as a therapeutic development company which focuses on regenerative and curative medicines. Its products include Provoque facial serum and Provoque eye complex. The company was founded by Hans S. Keirstead in 2016 and is headquartered in Irvine, CA.

Innoplexus AG provides consulting-led technology and product development services. It offers innovation management, bigdata and analytics, data virtualization, cloud computing, machine learning, network analysis and text analytics services. The company was founded by Gunjan Bhardwaj and Gaurav Tripathi in 2011 and is headquartered in Stuttgart, Germany.

Mindimmune Therapeutics, Inc. develops drugs that target the immune system to treat diseases of the central nervous system. It focuses on the treatment of Alzheimer's, Huntington's disease, pain, and psychiatric disorders. The company was founded by Stevin Zorn, Frank S. Menniti, Robert B. Nelson, and Brian M. Campbell on July 12, 2016 and is headquartered in Kingston, RI.

ATAI Life Sciences AG operates as a holding company, which is a global biotech company builder. The company was founded by Christian Angermayer, Lars Christian Wilde, Srinivas G. Rao and Florian Brand in 2018 and is headquartered in Munich, Germany.

Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY.

Part of Compass Pathways Plc, COMPASS Pathfinder Holdings Ltd. is an investment holding British company. The company is based in London, UK and was founded in 2017.

Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019.

EntheogeniX Biosciences, Inc. is a biotech company located in Wilmington, DE. EntheogeniX Biosciences is dedicated to advancing psychedelic research for the development of better medicines for mental health diseases such as depression, bipolar disorder, and schizophrenia. The joint venture company aims to innovate the mental healthcare system by harnessing the power of artificial intelligence and computational biophysics, along with a data-driven pipeline, to uncover new medicines from desired psychedelics to further help patients. EntheogeniX Biosciences is a partnership between atai life sciences and Cyclica. The company was founded by Naheed Kurji and is currently led by CEO Srinivas G. Rao since 2019.

EmpathBio operates as an biotechnology company. It engages in the provision of post-traumatic stress disorder (PTSD) psychotherapy. The firm develops 3,4-Methylenedioxy-methamphetamine (MDMA)derivatives in conjunction with digital therapeutics to deliver treatments to patients. The company was founded by Florian Brand and is headquartered in New York, NY.

IntroSpect Digital Therapeutics, Inc. provides digital therapeutic platform for mental health care and support. The firm is designed to extend the life changing potential of psychedelics-assisted psychotherapy to patients in a scalable way. The company was founded by David Keene, Srinivas G. Rao and Florian Brand and is headquartered in San Diego, CA.

Part of ATAI Life Sciences NV, Viridia Life Sciences, Inc. develops drug products. The company is based in Wilmington, DE. The company was founded by Florian Brand. The CEO is Glenn Short.

ImStar Therapeutics, Inc. develops therapies for ALS and neurodegenerative disease. The firm's lead drug candidate is IMS-088, a small-molecule compound currently in preclinical development. It is studying compounds directed at a proprietary new therapeutic target for ALS called TANA. The company was founded by Daniel J. Wattier and Jean-Pierre Julien in 2012 and is headquartered in Vancouver, Canada.